T6580

Triflusal

≥98% (HPLC), powder

• 동의어(들): Triflusal, α,α,α-trifluoro-2,4-cresotic acid acetate, 2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid, Drisgen, acetyl-4-trifluoromethylsalicylic acid
• 실험식(Hill 표기법): C₁₀H₇F₃O₄
• CAS Number: 322-79-2
• Molecular Weight: 248.16
• EC Number: 206-297-5
• UNSPSC 코드: 12352200
• NACRES: NA.25

속성

• Quality Level: 100
• 분석: ≥98% (HPLC)
• 양식: powder
• 색상: white to off-white
• solubility: DMSO: >30 mg/mL
• 주관자: Uriach
• 저장 온도: 2-8°C
• SMILES string: FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C
• InChI: 1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
• InChI key: RMWVZGDJPAKBDE-UHFFFAOYSA-N

설명

생화학적/생리학적 작용

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action.

Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.

특징 및 장점

This compound was developed by Uriach. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• 픽토그램: GHS07
• 신호어: Warning
• 유해 및 위험 성명서: H302,H315,H317,H319,H335
• 예방조치 성명서: P280 - P301 + P312 + P330 - P302 + P352 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
• 표적 기관: Respiratory system
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable